Tag Archives: with-the-center

Potential Drug Target May Curb Hospital-Acquired Infection

Posted on by

Newswise Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the bodys natural defenses into overdrive, actually intensifying illness while fighting infection. The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C. Continue reading →

Study of hospital-acquired infection yields potential therapeutic target

Posted on by

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body’s natural defenses into overdrive, actually intensifying illness while fighting infection. The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C Continue reading →

Researchers discover how C. diff red lines immune response

Posted on by

Public release date: 30-Nov-2012 [ | E-mail | Share ] Contact: Tiffany Trent ttrent@vt.edu 540-231-6822 Virginia Tech Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body’s natural defenses into overdrive, actually intensifying illness while fighting infection. Continue reading →

RetroSense Therapeutics Completes pre-IND Meeting for RST-001

Posted on by

ANN ARBOR, Mich.–(BUSINESS WIRE)– RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSenses lead biologic, RST-001 for vision restoration in retinal degenerative conditions. The purpose of the meeting was to obtain CBERs guidance for the clinical path to a Biologics License Application (BLA) for RST-001 in the US, and clarity on the steps required for Investigational New Drug (IND) submission. The discussions included manufacturing criteria, the scope and design of the preclinical studies, and the scope and design of Phase I and IIa clinical trials Continue reading →